> GlaxoSmithKline has returned Paxil CR to the market, three months after regulators found manufacturing problems at three of its facilities. Story [1]

> A European drug panel has recommended Roche's Tarceva for lung cancer. Story [2]

> The European Medicines Agency has recommended the continued suspension of Pfizer's Bextra with new warnings regarding all Cox-2 inhibitors. Story [3]

> Neurobiological Technologies has signed a manufacturing deal with Baxter and Nordmark for a Phase III trial of Viprinex. Release [4]

> Switzerland's Debiopharm and Neovacs have signed an equity and licensing deal for the development of Neovacs' anti-TNF-Alpha product. Release [5]

> The EU's Committee for Medicinal Products for Human Use has recommended approval of Schering's contrast agent, Vasovist. Article [6]

And Finally... Even as pharmaceutical drugs continue their double-digit rise in prices, generic drug prices are remaining steady. Story [7]